Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 27Myelodysplastic Syndromes 6Leukemia, Biphenotypic, Acute 4Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid 2Leukemia 2Blast Crisis 2Sarcoma, Myeloid 1Neoplasms by Histologic Type 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Carcinoma, Hepatocellular 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Injections 2Gemtuzumab 2Decitabine 2Cytarabine 2fludarabine phosphate 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Daunorubicin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Acute × Idarubicin × 90 days × Clear all
NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
270 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡